Skip to main content

Table 5 Association between metformin plus sodium-glucose transporter 2 inhibitors and metformin plus insulin and study outcomes before propensity score matching

From: Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Outcomes Treatment groups
  Metformin + SGLT-2i (n = 67) Other GLD (n = 583) p value
In-hospital deaths 13 (19.4%) 228 (39.1%) 0.003
ICU admission, mechanical ventilation, or in-hospital death 35 (52.2%) 375 (64.3%) 0.051
In-hospital complications 33 (49.3%) 351 (60.2%) 0.132
Long-time hospital stay 8 (11.9%) 130 (22.3%) 0.087
Metformin + insulin (n = 110) Other GLD (n = 1375) p value
In-hospital deaths 43 (39.1%) 445 (32.4%) 0.175
ICU admission, mechanical ventilation, or in-hospital death 76 (69.1%) 810 (58.9%) 0.084
In-hospital complications 73 (66.4%) 756 (55.0%) 0.030
Long-time hospital stay 21 (19.1%) 320 (23.3%) 0.360
  1. Data are shown as absolute values and percentages. Values were considered to be statistically significant when p < 0.05
  2. GLD glucose-lowering drugs, ICU intensive care unit, SGLT-2i sodium-glucose transporter 2 inhibitors